...
首页> 外文期刊>Brazilian Journal of Infectious Diseases >Detection of multidrug-resistant Mycobacterium tuberculosis strains isolated in Brazil using a multimarker genetic assay for katG and rpoB genes
【24h】

Detection of multidrug-resistant Mycobacterium tuberculosis strains isolated in Brazil using a multimarker genetic assay for katG and rpoB genes

机译:使用针对katG和rpoB基因的多标记遗传检测法检测在巴西分离的耐多药结核分枝杆菌菌株

获取原文
           

摘要

Multidrug-resistant tuberculosis (MDRTB) is a serious world health problem that limits public actions to control tuberculosis, because the most used anti-tuberculosis first-line drugs fail to stop mycobacterium spread. Consequently, a quick detection through molecular diagnosis is essential to reduce morbidity and medical costs. Despite the availability of several molecular-based commercial-kits to diagnose multidrug-resistant tuberculosis, their diagnostic value might diverge worldwide since Mycobacterium tuberculosis genetic variability differs according to geographic location. Here, we studied the predictive value of four common mycobacterial mutations in strains isolated from endemic areas of Brazil. Mutations were found at the frequency of 41.9% for katG, 25.6% for inhA, and 69.8% for rpoB genes in multidrug-resistant strains. Multimarker analysis revealed that combination of only two mutations (a€?katG/S315T + rpoB/S531La€?) was a better surrogate of multidrug-resistant tuberculosis than single-marker analysis (86% sensitivity vs. 62.8%). Prediction of multidrug-resistant tuberculosis was not improved by adding a third or fourth mutation in the model. Therefore, rather than using diagnostic kits detecting several mutations, we propose a simple dual-marker panel to detect multidrug-resistant tuberculosis, with 86% sensitivity and 100% specificity. In conclusion, this approach (previous genetic study + analysis of only prevalent markers) would considerably decrease the processing costs while retaining diagnostic accuracy.
机译:耐多药结核病(MDRTB)是一个严重的世界卫生问题,它限制了控制结核病的公共行动,因为最常用的抗结核一线药物无法阻止分枝杆菌的传播。因此,通过分子诊断的快速检测对于降低发病率和医疗费用至关重要。尽管有几种基于分子的商业试剂盒可用于诊断耐多药结核病,但由于结核分枝杆菌的遗传变异性因地理位置而异,因此其诊断价值可能在全球范围内有所不同。在这里,我们研究了从巴西流行地区分离出的菌株中四种常见分枝杆菌突变的预测价值。在多药耐药菌株中,katG的突变率为41.9%,inhA的突变为25.6%,rpoB基因的突变为69.8%。多标记分析显示,仅两个突变(katG / S315T + rpoB / S531La?)的组合比单标记分析更好地替代了多药耐药结核病(敏感性分别为86%和62.8%)。通过在模型中添加第三个或第四个突变,无法改善耐多药结核病的预测。因此,我们提议使用一个简单的双标记面板来检测耐多药结核病,而不是使用检测多种突变的诊断试剂盒,其灵敏度为86%,特异性为100%。总之,这种方法(以前的遗传研究+仅对流行标记的分析)将大大降低处理成本,同时又保持诊断准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号